{
    "clinical_study": {
        "@rank": "58598", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective, observational study will evaluate the efficacy, safety and tolerability of\n      RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid\n      arthritis who have had an inadequate response or are intolerant to one or more conventional\n      disease-modifying anti-rheumatic drugs. Data will be collected from patients initiated on\n      RoActemra/Actemra treatment according to the local label at baseline, Weeks 4, 12 and 24,\n      and at 3 and 6 months after the last dose of study drug."
        }, 
        "brief_title": "A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 21 years of age\n\n          -  Moderate to severe active rheumatoid arthritis (DAS28 >/= 3.2)\n\n          -  Inadequate response to one or more conventional disease-modifying anti-rheumatic\n             drugs (DMARDs)\n\n          -  Initiated on RoActemra/Actemra treatment in accordance with the prescribing\n             information\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  Contra-indication to RoActemra/Actemra treatment according to the local labelling\n\n          -  Previous treatment with tocilizumab\n\n          -  Treatment with any investigational agent within 4 weeks (or 5 half-lives of the\n             investigational agent, whichever is longer) before starting treatment with\n             RoActemra/Actemra\n\n          -  Women of childbearing potential not using effective methods of contraception as\n             defined by protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with moderate to severe rheumatoid arthritis and an inadequate response or\n        intolerant to previous therapy with conventional DMARDs"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01770834", 
            "org_study_id": "ML25533"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Safat", 
                        "country": "Kuwait", 
                        "zip": "13041"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon", 
                        "zip": "11-236"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon", 
                        "zip": "99999"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon", 
                        "zip": "470 Hazmieh"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon", 
                        "zip": "961"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jbeil", 
                        "country": "Lebanon", 
                        "zip": "1401"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saida", 
                        "country": "Lebanon", 
                        "zip": "652"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tripoli", 
                        "country": "Lebanon", 
                        "zip": "371 Tripoli"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Doha", 
                        "country": "Qatar", 
                        "zip": "3050"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dubai", 
                        "country": "United Arab Emirates", 
                        "zip": "P.O. Box 31500"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dubai", 
                        "country": "United Arab Emirates", 
                        "zip": "P.O. Box 8179"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Kuwait", 
                "Lebanon", 
                "Qatar", 
                "United Arab Emirates"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Non-interventional Multi-center Observational Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis in Routine Practice", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML25533 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Lebanon: Ministry of Public Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01770834"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients achieving a clinically meaningful improvement in disease activity: DAS28 reduction of at least 1.2 units, low disease activity (DAS28 </= 3.2) or remission (DAS28 <2.6)", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Clinical/demographic patient characteristics at initiation of RoActemra/Actemra treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Treatment regimens: Concomitant medications", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}